"uuid:ID","id","rationale","label","instanceType","name","description"
"0c1f16fa-2a7f-4ba2-ac19-690735684a24","StudyDesign_1","The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","","StudyDesign","Study Design 1","The main design for the study"
